Formycon AG

Formycon AG’s Q1 2026 results tripled revenue to €13.1 m, powered by FYB203 sales, while tightening EBITDA loss and boosting the biosimilar pipeline for future growth.

Formycon AG’s share plunge sparks debate: why investors should watch its biosimilar strategy and analyst‑forecasted 36 EUR upside.

Formycon AG’s modest XETRA recovery signals cautious investor optimism as the biopharma firm focuses on biosimilar development and contract services, aiming for long‑term growth despite current P/E challenges.

Formycon AG’s June 10, 2026 AGM in Munich focuses on 2025 results, governance updates, electronic shares, and profit‑transfer plans—key for shareholders to shape biopharma strategy.

Formycon AG’s 2025 earnings reveal modest revenue decline but disciplined cost control, boosting operating loss performance and strengthening biosimilar focus.

Formycon AG’s share sale by the Active Ownership Fund SICAV SIF SCS, led by supervisory‑board member Klaus Röhrig, signals a potential shift in investor confidence and may affect the biopharma firm’s stock and strategic outlook in the biosimilar mar…

Formycon AG faces market pressure after reporting a significant downturn in first-half revenues, but maintains an optimistic outlook for 2025 and reaffirms its 2025 guidance.

Formycon AG, a biopharmaceutical company, has seen significant stock price fluctuations, but early investors have reaped rewards, with a 5-year investment yielding a 35% return.

Formycon AG is navigating a challenging financial landscape, but remains optimistic about its future prospects in the biosimilar sector, despite a decline in revenue and market fluctuations.

Despite a significant decline in quarterly revenues, Formycon AG’s strategic foresight and operational tenacity position it for future growth in the rapidly expanding biosimilar market.